The firm expects 2025 revenues to shrink versus the prior year and business in China to dry up over the course of the year.
According to a new analysis, NIAID cut the most unexpended funding, $112.9 million, while Columbia University lost the largest number of grants, 157.
Glioma Study Unravels Molecular Features of Tumors From Adolescent, Young Adult Patients
Individuals with low-grade tumors and pediatric glioma-like alterations tended to have better progression-free survival and overall outcomes than others.
The firm booked $154.9 million in Q1 revenues, including $16.8 million in license and royalty revenues from the patent litigation settlement with Vizgen.
Natera Ramping up R&D, Commercial Spending as Q1 Product Revenues Rise 37 Percent, Beat Estimates
Premium
The firm trimmed its Q1 net loss and has begun investing heavily in R&D and commercial operations to drive future growth.
Veracyte Q1 Revenues up 18 Percent, Driven by Core Tests
The company continues to see increased adoption of its Decipher and Afirma tests, and said it is making changes to its IVD manufacturing business.
Twist Bioscience Nabs Long DNA IP in Renegotiated Ginkgo Bioworks Contract
The three-year $15 million agreement replaces a 2022 deal between the firms, which have been business partners since at least 2017.
Tempus AI Q1 Revenues Rise 75 Percent, Beat Wall Street Expectation
The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.